Wegwarth, O., Spies, C., Schulte, E., Meerpohl, J. J., Schmucker, C., Nury, E., Brockmann, D., Donner-Banzhoff, N., Wind, S., Goebel, E., Ludwig, W. D., & Hertwig, R. (2020). Experiencing the risk of overutilising opioids among patients with chronic non-cancer pain in ambulatory care (ERONA): The protocol of an exploratory, randomised controlled trial. BMJ Open, 10, Article e037642. https://doi.org/10.1136/bmjopen-2020-037642

Wegwarth, O., Wagner, G. G., Spies, C., & Hertwig, R. (2020). Assessment of German public attitudes toward health communications with varying degrees of scientific uncertainty regarding COVID-19. JAMA Network Open, 3(12), Article e2032335. https://doi.org/10.1001/jamanetworkopen.2020.32335

Gonzalez, A. I., Schmucker, C., Nothacker, J., Motschall, E., Nguyen, T. S., Brueckle, M.-S., Blom, J., van den Akker, M., Röttger, K., Wegwarth, O., Hoffmann, T., Straus, S. E., Gerlach, F. M., Meerpohl, J. J., & Muth, C. (2019). Health-related preferences of older patients with multimorbidity: An evidence map. BMJ Open, 9, Article e034485. https://doi.org/10.1136/bmjopen-2019-034485

González-González, A. I., Schmucker, C., Blom, J., van den Akker, M., Nguyen, T. S., Meerpohl, J., Röttger, K., Wegwarth, O., Hoffmann, T., Straus, S. E., Gerlach, F. M., & Muth, C. (2019). Health-related preferences of older patients with multimorbidity: The protocol for an evidence map. BMJ Open, 9, Article e029724. https://doi.org/10.1136/bmjopen-2019-029724

McDowell, M. E., Gigerenzer, G., Wegwarth, O., & Rebitschek, F. G. (2019). Effect of tabular and icon fact box formats on comprehension of benefits and harms of prostate cancer screening: A randomized trial. Medical Decision Making, 39(1), 41–56. https://doi.org/10.1177/0272989X18818166

Rebitschek, F. G., Pashayan, N., Widschwendter, M., & Wegwarth, O. (2019). Do cancer risk and benefit-harm ratios influence women's consideration of risk-reducing mastectomy? A scenario-based experiment in five European countries. PLoS ONE, 14(6), Article e0218188. https://doi.org/10.1371/journal.pone.0218188

Rebitschek, F. G., Reisel, D., Lein, I., & Wegwarth, O. (2019). Epigenetic risk assessment of female cancers: Women's information needs and attitudes. Public Health Genomics, 22(1-2), 46–57. https://doi.org/10.1159/000501975

Wegwarth, O., Pashayan, N., Widschwendter, M., & Rebitschek, F. G. (2019). Women's perception, attitudes, and intended behavior towards predictive epigenetic risk testing for female cancers in 5 European countries: A cross-sectional online survey. BMC Public Health, 19, Article 667. https://doi.org/10.1186/s12889-019-6994-8

Mühlbauer, V., Prinz, R., Mühlhauser, I., & Wegwarth, O. (2018). Alternative package leaflets improve people's understanding of drug side effects - A randomized controlled exploratory survey. PLoS ONE, 13(9), Article e0203800. https://doi.org/10.1371/journal.pone.0203800

Wegwarth, O. (2018). Brustkrebsfrüherkennung - Nutzen und Risiken richtig kommunizieren. Der Gynäkologe, 51(5), 370–379. https://doi.org/10.1007/s00129-018-4199-3

Wegwarth, O., & Gigerenzer, G. (2018). US gynecologists' estimates and beliefs regarding ovarian cancer screening's effectiveness 5 years after release of the PLCO evidence. Scientific Reports, 8, Article 17181. https://doi.org/10.1038/s41598-018-35585-z

Wegwarth, O., Widschwendter, M., Cibula, D., Sundström, K., Portuesi, R., Lein, I., Rebitschek, F. G., & FORECEE (4C) Consortium. (2018). What do European women know about their female cancer risks and cancer screening? A cross-sectional online intervention survey in five European countries. BMJ Open, 8, Article e023789. https://doi.org/10.1136/bmjopen-2018-023789

Widschwendter, M., Jones, A., Evans, I., Reisel, D., Dillner, J., Sundström, K., Steyerberg, E. W., Vergouwe, Y., Wegwarth, O., Rebitschek, F. G., Siebert, U., Sroczynski, G., de Beaufort, I. D., Bolt, I., Cibula, D., Zikan, M., Bjørge, L., Colombo, N., Harbeck, N., Dudbridge, F., Tasse, A.-M., Knoppers, B. M., Joly, Y., Teschendorff, A. E., Pashayan, N., & the FORECEE (4C) Consortium. (2018). Epigenome-based cancer risk prediction: Rationale, opportunities and challenges. Nature Reviews Clinical Oncology, 15(5), 292–309. https://doi.org/10.1038/nrclinonc.2018.30

Donner-Banzhoff, N., Seidel, J., Sikeler, A. M., Bösner, S., Vogelmeier, M., Westram, A., Feufel, M., Gaissmaier, W., Wegwarth, O., & Gigerenzer, G. (2017). The phenomenology of the diagnostic process: A primary-care based survey. Medical Decision Making, 37(1), 27–34. https://doi.org/10.1177/0272989X16653401

Wegwarth, O., Wagner, G. G., & Gigerenzer, G. (2017). Can facts trump unconditional trust? Evidence-based information halves the influence of physicians' non-evidence-based cancer screening recommendations. PLoS ONE, 12(8), Article e0183024. https://doi.org/10.1371/journal.pone.0183024

McDowell, M., Rebitschek, F. G., Gigerenzer, G., & Wegwarth, O. (2016). A simple tool for communicating the benefits and harms of health interventions: A guide for creating a fact box. MDM Policy & Practice, 1, Article 2381468316665365. https://doi.org/10.1177/2381468316665365

Prinz, R., Feufel, M. A., Gigerenzer, G., & Wegwarth, O. (2015). What counselors tell low-risk clients about HIV test performance. Current HIV Research, 13(5), 369–380. https://doi.org/10.2174/1570162X13666150511125200

Wegwarth, O. (2015). Medizinische Risikokommunikation: Nutzen und Schaden transparent kommunizieren. Forum: Das Offizielle Magazin der Deutschen Krebsgesellschaft e. V., 30(3), 208–213. https://doi.org/10.1007/s12312-015-1303-7

Wegwarth, O. (2015). Cancer survival rates: The CONCORD-2 study. The Lancet, 386(9992), 429–429. https://doi.org/10.1016/S0140-6736(15)61442-8

Wegwarth, O. (2014). Transparent risk communication in cancer screening: Reveal when it's good and when it's not. Oncology Research and Treatment, 37(Suppl. 3), 6–7. https://doi.org/10.1159/000367912